Ticker Details
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S and NeuVax.
IPO Date:	April 1, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.12B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.17 | 4.32%
Avg Daily Range (30 D):	$0.64 | 5.24%
Avg Daily Range (90 D):	$0.54 | 5.53%

Institutional Daily Volume
Avg Daily Volume:	1.21M
Avg Daily Volume (30 D):	6.27M
Avg Daily Volume (90 D):	7.87M

Trade Size
Avg Trade Size (Sh.):	404
Avg Trade Size (Sh.) (30 D):	152
Avg Trade Size (Sh.) (90 D):	188

Institutional Trades
Total Institutional Trades:	446
Avg Institutional Trade:	$2.26M
Avg Institutional Trade (30 D):	$2.2M
Avg Institutional Trade (90 D):	$2.56M
Avg Institutional Trade Volume:	.33M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.18M
Avg Closing Trade (30 D):	$4.15M
Avg Closing Trade (90 D):	$4.23M
Avg Closing Volume:	484.22K

News

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Jul 16, 2025 @ 10:51 PM Cancer Pipeline Milestones Coming Fast as Regulato... Source: Prnewswire

Jun 2, 2025 @ 12:00 PM SELLAS Presents Preclinical Efficacy of SLS009 in ... Source: Sellas Life Sciences Group, Inc.

May 12, 2025 @ 5:00 PM Blood Cancer Treatment Market Sees Accelerated Gro... Source: Delveinsight

Feb 27, 2025 @ 3:04 PM Oncology Breakthroughs: How Cancer Research Is Adv... Source: Prnewswire

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.21	$-.05	$-.05
Diluted EPS	$-.21	$-.05	$-.05
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-32.46M	$-9.61M	$-8.41M
Operating Income / Loss	$-35.22M	$-10.63M	$-9.25M
Cost of Revenue	$M	$M	$M
Net Cash Flow	$M	$M	$M
PE Ratio

Splits
Nov 08, 2019	1:50
Jan 02, 2018	1:30
Nov 14, 2016	1:20